StockSelector.com
  Research, Select, & Monitor Tuesday, August 22, 2017 10:21:30 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Johnson & Johnson$134.70$1.25.94%

  Quote | Ranking | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

 Johnson & Johnson Reports 2016 Third-Quarter Results:
   Tuesday, October 18, 2016 6:40:00 AM ET

Johnson & Johnson (JNJ ) today announced sales of $17.8 billion for the third quarter of 2016, an increase of 4.2% as compared to the third quarter of 2015. Operational sales results increased 4.3% and the negative impact of currency was 0.1%. Domestic sales increased 6.7%. International sales increased 1.5%, reflecting operational growth of 1.7% and a negative currency impact of 0.2%. Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 5.9%, domestic sales increased 7.3% and international sales increased 4.2%.* Operations in Venezuela negatively impacted worldwide operational sales growth by 30 basis points, and international sales growth by 70 basis points.

Net earnings and diluted earnings per share for the third quarter of 2016 were $4.3 billion and $1.53, respectively. Third quarter 2016 net earnings included after-tax intangible amortization expense of approximately $0.2 billion and a charge for after-tax special items of approximately $0.2 billion. Third quarter 2015 net earnings included after-tax intangible amortization expense of approximately $0.4 billion and a charge for after-tax special items of approximately $0.4 billion. Excluding after-tax intangible amortization expense and special items, adjusted net earnings for the current quarter were $4.7 billion and adjusted diluted earnings per share were $1.68, representing increases of 12.2% and 12.8%, respectively, as compared to the same period in 2015.* On an operational basis, adjusted diluted earnings per share also increased 12.8%.* A reconciliation of non-GAAP financial measures is included as an accompanying schedule.

"Our third-quarter results reflect the success of our new product launches and the strength of our core businesses, driven by strong growth in our Pharmaceuticals business. With a number of regulatory approvals, several new drug application submissions and new breakthrough therapy designations from the FDA, we are increasingly confident in our pipeline expectation of filing 10 new pharmaceutical products between 2015 and 2019, each with revenue potential over $1 billion," said Alex Gorsky, Chairman and Chief Executive Officer. "Our broad-based business model, strategic investments and talented colleagues position us well for continued leadership in health care."

The Company maintained its sales guidance for the full-year 2016 of $71.5 billion to $72.2 billion. Additionally, the Company increased its adjusted earnings guidance for full-year 2016 to $6.68 - $6.73 per share.*

Worldwide Consumer sales of $3.3 billion for the third quarter 2016 represented a decrease of 1.6% versus the prior year, consisting of an operational increase of 0.1% and a negative impact from currency of 1.7%. Domestic sales increased 1.1%; international sales decreased 3.3%, which reflected an operational decrease of 0.6% and a negative currency impact of 2.7%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales decreased 0.4%, domestic sales decreased 1.5% and international sales increased 0.3%*. Operations in Venezuela negatively impacted worldwide Consumer operational sales growth by 110 basis points and international sales growth by 180 basis points.

Worldwide operational results, excluding the net impact of acquisitions and divestitures, were negatively impacted by lower trade inventory levels, primarily in the U.S. Positive contributors to Consumer operational sales results included LISTERINE? oral care products; AVEENO? skin care products and digestive health products and international smoking aids in over-the-counter products.

Worldwide Pharmaceutical sales of $8.4 billion for the third quarter 2016 represented an increase of 9.2% versus the prior year with an operational increase of 9.0% and a positive impact from currency of 0.2%. Domestic sales increased 11.8%; international sales increased 5.4%, which reflected an operational increase of 5.0% and a positive currency impact of 0.4%. Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 10.7%, domestic sales increased 13.0% and international sales increased 7.0%.*

Worldwide operational results, excluding the net impact of acquisitions, divestitures and hepatitis C sales, were driven by new products and the strength of core products. Strong growth in new products include IMBRUVICA? (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer; DARZALEX? (daratumumab), for the treatment of patients with multiple myeloma; and XARELTO? (rivaroxaban), an oral anticoagulant.

Additional contributors to operational sales growth included STELARA? (ustekinumab), REMICADE? (infliximab) and SIMPONI?/SIMPONI ARIA? (golimumab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases; and INVEGA? SUSTENNA?/XEPLION?/TRINZA? (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults.

During the quarter, the U.S. Food and Drug Administration (FDA) approved INVOKAMET? XR (canagliflozin/metformin HCl extended-release) for first-line treatment of adults with type 2 diabetes, and STELARA? (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease. The Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of STELARA? for the treatment of adults with moderately to severely active Crohn’s disease.

Additionally, regulatory applications for approval were submitted to the FDA and European Medicines Agency (EMA) for DARZALEX? in combination with standard-of-care regimens for patients with multiple myeloma who have received at least one prior therapy. DARZALEX? also received Breakthrough Therapy Designation from the FDA for this pending indication. The FDA also granted Breakthrough Therapy Designation to esketamine for major depressive disorder with imminent risk for suicide. Regulatory applications for approval were also submitted to the FDA for sirukumab in rheumatoid arthritis, and to EMA for a darunavir-based single tablet regimen for the treatment of HIV-1.

Worldwide Medical Devices sales of $6.2 billion for the third quarter 2016 represented an increase of 1.1% versus the prior year consisting of an operational increase of 0.7% and a positive currency impact of 0.4%. Domestic sales increased 1.4%; international sales increased 0.7%, which reflected an operational decline of 0.2% and a positive currency impact of 0.9%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 3.1%, domestic sales increased 2.3% and international sales increased 3.9%.*

Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by electrophysiology products in the Cardiovascular business; endocutters and energy in the Advanced Surgery business; ACUVUE? contact lenses in the Vision Care business; and joint reconstruction and trauma products in the Orthopaedics business.

During the quarter, a definitive agreement was announced to acquire Abbott Medical Optics, a wholly-owned subsidiary of Abbott Laboratories, for $4.325 billion in cash. Acclarent announced the U.S. launch of ACCLARENT AERA(TM), the first balloon dilation intervention approved by the FDA for Eustachian Tube Dysfunction.

About Johnson & Johnson

Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,900 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Operational sales growth excluding the net impact of acquisitions, divestitures and hepatitis C sales, as well as adjusted net earnings, adjusted diluted earnings per share and operational adjusted diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company’s website at www.investor.jnj.com. Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson’s results computed in accordance with GAAP.

Johnson & Johnson will conduct a conference call with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can be found on the company’s website at www.investor.jnj.com.

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans, including restructuring plans; market conditions and the possibility that the on-going share repurchase program may be delayed, suspended or discontinued; the impact of business combinations and divestitures; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; increased scrutiny of the health care industry by government agencies; and the potential failure to meet obligations in compliance agreements with government bodies. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 3, 2016, including in Exhibit 99 thereto, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)   THIRD QUARTER                                     NINE MONTHS
                                                      Percent Change                                    Percent Change
                                   2016       2015    Total    Operations  Currency  2016       2015    Total    Operations  Currency
Sales to customers by
segment of business
Consumer
U.S.                               $   1,291  1,277   1.1   %  1.1         -         $   4,033  3,991   1.1   %  1.1         -
International                      1,970      2,037   (3.3)    (0.6)       (2.7)     5,842      6,196   (5.7)    0.1         (5.8)
                                   3,261      3,314   (1.6)    0.1         (1.7)     9,875      10,187  (3.1)    0.4         (3.5)
Pharmaceutical
U.S.                               5,042      4,509   11.8     11.8        -         15,123     13,423  12.7     12.7        -
International                      3,358      3,185   5.4      5.0         0.4       10,109     9,943   1.7      4.2         (2.5)
                                   8,400      7,694   9.2      9.0         0.2       25,232     23,366  8.0      9.1         (1.1)
Medical Devices
U.S.                               3,048      3,005   1.4      1.4         -         9,118      8,980   1.5      1.5         -
International                      3,111      3,089   0.7      (0.2)       0.9       9,559      9,730   (1.8)    0.5         (2.3)
                                   6,159      6,094   1.1      0.7         0.4       18,677     18,710  (0.2)    1.0         (1.2)
U.S.                               9,381      8,791   6.7      6.7         -         28,274     26,394  7.1      7.1         -
International                      8,439      8,311   1.5      1.7         (0.2)     25,510     25,869  (1.4)    1.8         (3.2)
Worldwide                          $ 17,820   17,102  4.2   %  4.3         (0.1)     $ 53,784   52,263  2.9   %  4.5         (1.6)
Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)   THIRD QUARTER                                     NINE MONTHS
                                                      Percent Change                                   Percent Change
                                   2016       2015    Total    Operations  Currency  2016      2015    Total    Operations  Currency
Sales to customers by
geographic area
U.S.                               $   9,381  8,791   6.7   %  6.7         -         $ 28,274  26,394  7.1   %  7.1         -
Europe                             3,832      3,802   0.8      3.2         (2.4)     11,769    11,993  (1.9)    0.5         (2.4)
Western Hemisphere excluding U.S.  1,396      1,463   (4.6)    (1.3)       (3.3)     4,269     4,603   (7.3)    4.4         (11.7)
Asia-Pacific, Africa               3,211      3,046   5.4      1.4         4.0       9,472     9,273   2.1      2.1         0.0
International                      8,439      8,311   1.5      1.7         (0.2)     25,510    25,869  (1.4)    1.8         (3.2)
Worldwide                          $ 17,820   17,102  4.2   %  4.3         (0.1)     $ 53,784  52,263  2.9   %  4.5         (1.6)
Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)                 THIRD QUARTER
                                                                  2016                             2015                           Percent
                                                                                       Percent                          Percent   Increase
                                                                  Amount               to Sales    Amount               to Sales  (Decrease)
Sales to customers                                                $         17,820     100.0       $         17,102     100.0     4.2
Cost of products sold                                             5,486                30.8        5,224                30.5      5.0
Selling, marketing and administrative expenses                    4,772                26.8        5,081                29.7      (6.1)
Research and development expense                                  2,178                12.2        2,154                12.6      1.1
In-process research and development                               -                    -           10                   0.1
Interest (income) expense, net                                    95                   0.5         91                   0.5
Other (income) expense, net                                       (54)                 (0.2)       420                  2.5
Restructuring                                                     62                   0.3         -                    -
Earnings before provision for taxes on income                     5,281                29.6        4,122                24.1      28.1
Provision for taxes on income                                     1,009                5.6         764                  4.5       32.1
Net earnings                                                      $           4,272    24.0        $           3,358    19.6      27.2
Net earnings per share (Diluted)                                  $             1.53               $             1.20             27.5
Average shares outstanding (Diluted)                              2,785.4                          2,807.2
Effective tax rate                                                19.1               %             18.5               %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income                     $           5,831    32.7        $           5,212    30.5      11.9
Net earnings                                                      $           4,683    26.3        $           4,172    24.4      12.2
Net earnings per share (Diluted)                                  $             1.68               $             1.49             12.8
Effective tax rate                                                19.7               %             20.0               %
(1) See Reconciliation of Non-GAAP Financial Measures.
Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)                 NINE MONTHS
                                                                  2016                                2015                           Percent
                                                                                       Percent                             Percent   Increase
                                                                  Amount               to Sales       Amount               to Sales  (Decrease)
Sales to customers                                                $         53,784     100.0          $         52,263     100.0     2.9
Cost of products sold                                             16,151               30.0           15,863               30.4      1.8
Selling, marketing and administrative expenses                    14,636               27.2           15,312               29.3      (4.4)
Research and development expense                                  6,455                12.0           6,182                11.8      4.4
In-process research and development                               29                   0.1            10                   0.0
Interest (income) expense, net                                    274                  0.5            317                  0.6
Other (income) expense, net                                       464                  0.9            (859)                (1.6)
Restructuring                                                     296                  0.5            -                    -
Earnings before provision for taxes on income                     15,479               28.8           15,438               29.5      0.3
Provision for taxes on income                                     2,753                5.1            3,244                6.2       (15.1)
Net earnings                                                      $         12,726     23.7           $         12,194     23.3      4.4
Net earnings per share (Diluted)                                  $             4.55                  $             4.33             5.1
Average shares outstanding (Diluted)                              2,796.6                             2,817.1
Effective tax rate                                                17.8               %                21.0               %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income                     $         17,656     32.8           $         17,090     32.7      3.3
Net earnings                                                      $         14,403     26.8           $         13,402     25.6      7.5
Net earnings per share (Diluted)                                  $             5.15                  $             4.76             8.2
Effective tax rate                                                18.4               %                21.6               %
(1) See Reconciliation of Non-GAAP Financial Measures.
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
                                                                                                 Third Quarter        % Incr. /    Nine Months YTD       % Incr. /
(Dollars in Millions Except Per Share Data)                                                      2016       2015      (Decr.)      2016        2015      (Decr.)
Earnings before provision for taxes on income - as reported                                      $ 5,281    4,122     28.1      %  $ 15,479    15,438    0.3       %
Intangible asset amortization expense                                                            319        639                    927         1,269
Restructuring/Other (1)                                                                          109        -                      387         -
Litigation expense, net                                                                          55         409                    721         141
DePuy ASR(TM) Hip program                                                                        -          -                      -           148
In-process research and development                                                              -          10                     29          10
Other                                                                                            67         32                     113         84
Earnings before provision for taxes on income - as adjusted                                      $ 5,831    5,212     11.9      %  $ 17,656    17,090    3.3       %
Net Earnings - as reported                                                                       $ 4,272    3,358     27.2      %  $ 12,726    12,194    4.4       %
Intangible asset amortization expense                                                            236        437                    679         893
Restructuring/Other                                                                              76         -                      293         -
Litigation expense, net                                                                          46         348                    595         118
DePuy ASR(TM) Hip program                                                                        -          -                      -           130
In-process research and development                                                              -          6                      23          6
Other                                                                                            53         23                     87          61
Net Earnings - as adjusted                                                                       $ 4,683    4,172     12.2      %  $ 14,403    13,402    7.5       %
Diluted Net Earnings per share - as reported                                                     $   1.53   1.20      27.5      %  $     4.55  4.33      5.1       %
Intangible asset amortization expense                                                            0.08       0.16                   0.24        0.32
Restructuring/Other                                                                              0.03       -                      0.11        -
Litigation expense, net                                                                          0.02       0.12                   0.21        0.04
DePuy ASR(TM) Hip program                                                                        -          -                      -           0.05
In-process research and development                                                              -          -                      0.01        -
Other                                                                                            0.02       0.01                   0.03        0.02
Diluted Net Earnings per share - as adjusted                                                     $   1.68   1.49      12.8      %  $     5.15  4.76      8.2       %
Operational Diluted Net Earnings per share - as adjusted at 2014 foreign currency exchange rates            1.63                               5.22
Impact of currency at 2015 foreign currency exchange rates                                       $       -  (0.14)                 $     0.04  (0.46)
Operational Diluted Net Earnings per share - as adjusted at 2015 foreign currency exchange rates $   1.68   1.49      12.8      %  $     5.19  4.76      9.0       %
(1) Includes $3M recorded in cost of products sold and $44M recorded in other (income) expense for the third quarter.
Includes $27M recorded in cost of products sold and $64M recorded in other (income) expense for nine months YTD.
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Operational Sales Growth Excluding Acquisitions, Divestitures, and Hepatitis C Sales(1)
THIRD QUARTER 2016 ACTUAL vs. 2015 ACTUAL
Segments
                                                             Consumer     Pharmaceutical  Medical Devices  Total
                                                             Operational %(2)
WW As Reported:                                              0.1%         9.0%            0.7%             4.3%
U.S.                                                         1.1%         11.8%           1.4%             6.7%
International                                                (0.6)%       5.0%            (0.2)%           1.7%
Wound Care/Other
SPLENDA?                                                     2.1                                           0.4
U.S.                                                         4.0                                           0.6
International                                                1.0                                           0.2
Cardiovascular
Cordis                                                                                    2.3              0.9
U.S.                                                                                      1.1              0.4
International                                                                             3.7              1.4
Skin Care                                                    (2.3)
Vogue                                                        (5.8)                                         (0.4)
U.S.                                                         0.0                                           (0.8)
International                                                                                              0.0
Other Neuroscience
Controlled Substance Raw Material and API Business                        0.7                              0.3
U.S.                                                                      0.9                              0.4
International                                                             0.4                              0.1
All Other Acquisitions and Divestitures                      (0.3)        0.0             0.1              0.0
U.S.                                                         (0.8)        0.0             (0.2)            (0.2)
International                                                (0.1)        0.0             0.4              0.2
WW Ops excluding Acquisitions and Divestitures               (0.4)%       9.7%            3.1%             5.5%
U.S.                                                         (1.5)%       12.7%           2.3%             7.1%
International                                                0.3%         5.4%            3.9%             3.6%
Hepatitis C                                                               1.0                              0.4
U.S.                                                                      0.3                              0.2
International                                                             1.6                              0.6
WW Ops excluding Hepatitis C only                                         10.0%                            4.7%
U.S.                                                                      12.1%                            6.9%
International                                                             6.6%                             2.3%
WW Ops excluding Acquisitions, Divestitures and Hepatitis C  (0.4)%       10.7%           3.1%             5.9%
U.S.                                                         (1.5)%       13.0%           2.3%             7.3%
International                                                0.3%         7.0%            3.9%             4.2%
(1) Hepatitis C products include OLYSIO?/SOVRIAD?and INCIVO?
(2) Operational growth excludes the effect of translational currency
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Operational Sales Growth Excluding Acquisitions, Divestitures, and Hepatitis C Sales(1)
NINE MONTHS 2016 ACTUAL vs. 2015 ACTUAL
Segments
                                                              Consumer      Pharmaceutical  Medical Devices  Total
                                                              Operational %(2)
WW As Reported:                                               0.4%          9.1%            1.0%             4.5%
U.S.                                                          1.1%          12.7%           1.5%             7.1%
International                                                 0.1%          4.2%            0.5%             1.8%
Wound Care/Other
SPLENDA?                                                      2.2                                            0.4
U.S.                                                          4.3                                            0.7
International                                                 0.9                                            0.2
Cardiovascular
Cordis                                                                                      2.4              0.9
U.S.                                                                                        1.1              0.4
International                                                                               3.5              1.3
Skin Care                                                     (0.7)
Vogue                                                         (1.9)                                          (0.1)
U.S.                                                          0.0                                            (0.3)
International                                                                                                0.0
All Other Acquisitions and Divestitures                       (0.1)         0.4             0.0              0.1
U.S.                                                          (0.3)         0.7             (0.1)            0.2
International                                                 0.0           0.0             0.1              0.1
WW Ops excluding Acquisitions and Divestitures                1.8%          9.5%            3.4%             5.8%
U.S.                                                          3.2%          13.4%           2.5%             8.1%
International                                                 1.0%          4.2%            4.1%             3.4%
Hepatitis C                                                                 2.4                              1.1
U.S.                                                                        1.1                              0.6
International                                                               4.2                              1.6
WW Ops excluding Hepatitis C only                                           11.5%                            5.6%
U.S.                                                                        13.8%                            7.7%
International                                                               8.4%                             3.4%
WW Ops excluding Acquisitions, Divestitures, and Hepatitis C  1.8%          11.9%           3.4%             6.9%
U.S.                                                          3.2%          14.5%           2.5%             8.7%
International                                                 1.0%          8.4%            4.1%             5.0%
(1) Hepatitis C products include OLYSIO?/SOVRIAD?and INCIVO?
(2) Operational growth excludes the effect of translational currency
                                          REPORTED SALES vs. PRIOR PERIOD ($MM)
                                          THIRD QUARTER                                                       NINE MONTHS
                                                                           % Change                                                             % Change
                                                     2016            2015  Reported Operational (1) Currency     2016             2015          Reported Operational (1) Currency
CONSUMER SEGMENT (2)
BABY CARE
US                                                   $           96  103   -6.8%    -6.8%           -            $           293  $         318 -7.9%    -7.9%           -
Intl                                                 370             403   -8.2%    -5.3%           -2.9%        1,124            1,242         -9.5%    -2.5%           -7.0%
WW                                                   466             506   -7.9%    -5.6%           -2.3%        1,417            1,560         -9.2%    -3.6%           -5.6%
ORAL CARE
US                                                   156             154   1.3%     1.3%            -            485              459           5.7%     5.7%            -
Intl                                                 227             224   1.3%     3.1%            -1.8%        686              713           -3.8%    1.8%            -5.6%
WW                                                   383             378   1.3%     2.3%            -1.0%        1,171            1,172         -0.1%    3.3%            -3.4%
OTC
US                                                   380             383   -0.8%    -0.8%           -            1,230            1,154         6.6%     6.6%            -
Intl                                                 584             580   0.7%     3.5%            -2.8%        1,761            1,776         -0.8%    4.2%            -5.0%
WW                                                   964             963   0.1%     1.8%            -1.7%        2,991            2,930         2.1%     5.1%            -3.0%
SKIN CARE
US                                                   517             435   18.9%    18.9%           -            1,560            1,418         10.0%    10.0%           -
Intl                                                 438             428   2.3%     5.3%            -3.0%        1,210            1,242         -2.6%    2.7%            -5.3%
WW                                                   955             863   10.7%    12.2%           -1.5%        2,770            2,660         4.1%     6.6%            -2.5%
WOMEN’S HEALTH
US                                                   3               6     -50.0%   -50.0%          -            16               19            -15.8%   -15.8%          -
Intl                                                 266             304   -12.5%   -9.1%           -3.4%        787              898           -12.4%   -5.1%           -7.3%
WW                                                   269             310   -13.2%   -9.9%           -3.3%        803              917           -12.4%   -5.3%           -7.1%
WOUND CARE / OTHER
US                                                   139             196   -29.1%   -29.1%          -            449              623           -27.9%   -27.9%          -
Intl                                                 85              98    -13.3%   -13.2%          -0.1%        274              325           -15.7%   -12.0%          -3.7%
WW                                                   224             294   -23.8%   -23.8%          0.0%         723              948           -23.7%   -22.4%          -1.3%
TOTAL CONSUMER
US                                                   1,291           1,277 1.1%     1.1%            -            4,033            3,991         1.1%     1.1%            -
Intl                                                 1,970           2,037 -3.3%    -0.6%           -2.7%        5,842            6,196         -5.7%    0.1%            -5.8%
WW                                                   $      3,261    3,314 -1.6%    0.1%            -1.7%        $        9,875   10,187        -3.1%    0.4%            -3.5%
                                          REPORTED SALES vs. PRIOR PERIOD ($MM)
                                          THIRD QUARTER                                                       NINE MONTHS
                                                                           % Change                                                             % Change
                                                     2016            2015  Reported Operational (1) Currency     2016             2015          Reported Operational (1) Currency
PHARMACEUTICAL SEGMENT (2)
IMMUNOLOGY
US                                                   $      2,294    1,910 20.1%    20.1%           -            $        6,689   5,541         20.7%    20.7%           -
Intl                                                 790             704   12.2%    11.6%           0.6%         2,343            2,090         12.1%    15.7%           -3.6%
WW                                                   3,084           2,614 18.0%    17.8%           0.2%         9,032            7,631         18.4%    19.4%           -1.0%
REMICADE
US                                                   1,222           1,117 9.4%     9.4%            -            3,669            3,260         12.5%    12.5%           -
US Exports (3)                                       255             180   41.7%    41.7%           -            673              602           11.8%    11.8%           -
Intl                                                 306             316   -3.2%    -2.9%           -0.3%        1,000            1,019         -1.9%    3.4%            -5.3%
WW                                                   1,783           1,613 10.5%    10.6%           -0.1%        5,342            4,881         9.4%     10.5%           -1.1%
SIMPONI / SIMPONI ARIA
US                                                   256             199   28.6%    28.6%           -            716              526           36.1%    36.1%           -
Intl                                                 225             181   24.3%    20.6%           3.7%         603              462           30.5%    31.3%           -0.8%
WW                                                   481             380   26.6%    24.8%           1.8%         1,319            988           33.5%    33.9%           -0.4%
STELARA
US                                                   561             414   35.5%    35.5%           -            1,631            1,153         41.5%    41.5%           -
Intl                                                 253             199   27.1%    27.8%           -0.7%        722              579           24.7%    27.2%           -2.5%
WW                                                   814             613   32.8%    33.0%           -0.2%        2,353            1,732         35.9%    36.7%           -0.8%
OTHER IMMUNOLOGY
US                                                   -               -     -        -               -            -                -             -        -               -
Intl                                                 6               8     -25.0%   -22.6%          -2.4%        18               30            -40.0%   -32.9%          -7.1%
WW                                                   6               8     -25.0%   -22.6%          -2.4%        18               30            -40.0%   -32.9%          -7.1%
INFECTIOUS DISEASES
US                                                   387             379   2.1%     2.1%            -            1,107            1,172         -5.5%    -5.5%           -
Intl                                                 455             469   -3.0%    -2.2%           -0.8%        1,340            1,683         -20.4%   -18.5%          -1.9%
WW                                                   842             848   -0.7%    -0.3%           -0.4%        2,447            2,855         -14.3%   -13.2%          -1.1%
EDURANT
US                                                   13              11    18.2%    18.2%           -            38               29            31.0%    31.0%           -
Intl                                                 136             100   36.0%    35.4%           0.6%         370              274           35.0%    35.2%           -0.2%
WW                                                   149             111   34.2%    33.7%           0.5%         408              303           34.7%    34.9%           -0.2%
OLYSIO / SOVRIAD
US                                                   13              26    -50.0%   -50.0%          -            50               174           -71.3%   -71.3%          -
Intl                                                 8               53    -84.9%   -85.7%          0.8%         46               403           -88.6%   -88.2%          -0.4%
WW                                                   21              79    -73.4%   -73.9%          0.5%         96               577           -83.4%   -83.1%          -0.3%
PREZISTA / PREZCOBIX / REZOLSTA
US                                                   310             285   8.8%     8.8%            -            860              777           10.7%    10.7%           -
Intl                                                 183             183   0.0%     2.0%            -2.0%        544              566           -3.9%    -1.1%           -2.8%
WW                                                   493             468   5.3%     6.1%            -0.8%        1,404            1,343         4.5%     5.7%            -1.2%
OTHER INFECTIOUS DISEASES
US                                                   51              57    -10.5%   -10.5%          -            159              192           -17.2%   -17.2%          -
Intl                                                 128             133   -3.8%    -3.0%           -0.8%        380              440           -13.6%   -10.6%          -3.0%
WW                                                   179             190   -5.8%    -5.2%           -0.6%        539              632           -14.7%   -12.6%          -2.1%
See footnotes at end of schedule
                                                     REPORTED SALES vs. PRIOR PERIOD ($MM)
                                          THIRD QUARTER                                                       NINE MONTHS
                                                                           % Change                                                             % Change
                                                     2016            2015  Reported Operational (1) Currency     2016             2015          Reported Operational (1) Currency
NEUROSCIENCE
US                                                   622             655   -5.0%    -5.0%           -            1,997            2,098         -4.8%    -4.8%           -
Intl                                                 842             821   2.6%     0.0%            2.6%         2,618            2,560         2.3%     3.5%            -1.2%
WW                                                   1,464           1,476 -0.8%    -2.2%           1.4%         4,615            4,658         -0.9%    -0.2%           -0.7%
CONCERTA / METHYLPHENIDATE
US                                                   102             89    14.6%    14.6%           -            365              317           15.1%    15.1%           -
Intl                                                 88              89    -1.1%    -2.5%           1.4%         294              291           1.0%     4.4%            -3.4%
WW                                                   190             178   6.7%     6.0%            0.7%         659              608           8.4%     10.0%           -1.6%
INVEGA
US                                                   28              82    -65.9%   -65.9%          -            70               281           -75.1%   -75.1%          -
Intl                                                 59              57    3.5%     -1.0%           4.5%         185              179           3.4%     2.7%            0.7%
WW                                                   87              139   -37.4%   -39.2%          1.8%         255              460           -44.6%   -44.9%          0.3%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA
US                                                   339             277   22.4%    22.4%           -            983              758           29.7%    29.7%           -
Intl                                                 217             182   19.2%    18.8%           0.4%         646              548           17.9%    19.8%           -1.9%
WW                                                   556             459   21.1%    20.9%           0.2%         1,629            1,306         24.7%    25.5%           -0.8%
RISPERDAL CONSTA
US                                                   94              103   -8.7%    -8.7%           -            289              306           -5.6%    -5.6%           -
Intl                                                 128             132   -3.0%    -3.9%           0.9%         394              430           -8.4%    -7.1%           -1.3%
WW                                                   222             235   -5.5%    -6.0%           0.5%         683              736           -7.2%    -6.4%           -0.8%
OTHER NEUROSCIENCE
US                                                   59              104   -43.3%   -43.3%          -            290              436           -33.5%   -33.5%          -
Intl                                                 350             361   -3.0%    -7.3%           4.3%         1,099            1,112         -1.2%    -0.6%           -0.6%
WW                                                   409             465   -12.0%   -15.3%          3.3%         1,389            1,548         -10.3%   -9.9%           -0.4%
ONCOLOGY
US                                                   622             394   57.9%    57.9%           -            1,740            1,090         59.6%    59.6%           -
Intl                                                 895             776   15.3%    15.4%           -0.1%        2,605            2,332         11.7%    14.1%           -2.4%
WW                                                   1,517           1,170 29.7%    29.7%           0.0%         4,345            3,422         27.0%    28.7%           -1.7%
IMBRUVICA
US                                                   179             98    82.7%    82.7%           -            455              253           79.8%    79.8%           -
Intl                                                 170             86    97.7%    *               **           450              201           *        *               **
WW                                                   349             184   89.7%    92.1%           -2.4%        905              454           99.3%    *               **
VELCADE
US                                                   -               -     -        -               -            -                -             -        -               -
Intl                                                 304             329   -7.6%    -7.4%           -0.2%        950              1,012         -6.1%    -3.7%           -2.4%
WW                                                   304             329   -7.6%    -7.4%           -0.2%        950              1,012         -6.1%    -3.7%           -2.4%
ZYTIGA
US                                                   282             276   2.2%     2.2%            -            840              784           7.1%     7.1%            -
Intl                                                 300             272   10.3%    8.5%            1.8%         901              866           4.0%     5.4%            -1.4%
WW                                                   582             548   6.2%     5.3%            0.9%         1,741            1,650         5.5%     6.3%            -0.8%
OTHER ONCOLOGY
US                                                   161             20    *        *               -            445              53            *        *               -
Intl                                                 121             89    36.0%    36.6%           -0.6%        304              253           20.2%    23.0%           -2.8%
WW                                                   282             109   *        *               **           749              306           *        *               **
CARDIOVASCULAR / METABOLISM / OTHER
US                                                   1,117           1,171 -4.6%    -4.6%           -            3,590            3,522         1.9%     1.9%            -
Intl                                                 376             415   -9.4%    -7.4%           -2.0%        1,203            1,278         -5.9%    -1.5%           -4.4%
WW                                                   1,493           1,586 -5.9%    -5.4%           -0.5%        4,793            4,800         -0.1%    1.1%            -1.2%
XARELTO
US                                                   529             461   14.8%    14.8%           -            1,690            1,374         23.0%    23.0%           -
Intl                                                 -               -     -        -               -            -                -             -        -               -
WW                                                   529             461   14.8%    14.8%           -            1,690            1,374         23.0%    23.0%           -
INVOKANA / INVOKAMET
US                                                   294             322   -8.7%    -8.7%           -            939              890           5.5%     5.5%            -
Intl                                                 34              18    88.9%    94.3%           -5.4%        97               46            *        *               **
WW                                                   328             340   -3.5%    -3.2%           -0.3%        1,036            936           10.7%    11.3%           -0.6%
PROCRIT / EPREX
US                                                   168             177   -5.1%    -5.1%           -            581              519           11.9%    11.9%           -
Intl                                                 82              86    -4.7%    -4.7%           0.0%         265              289           -8.3%    -5.5%           -2.8%
WW                                                   250             263   -4.9%    -4.9%           0.0%         846              808           4.7%     5.7%            -1.0%
OTHER
US                                                   126             211        -40.3%     -40.3%          -              380              739           -48.6%   -48.6%          -
Intl                                                 260             311        -16.4%     -14.1%          -2.3%          841              943           -10.8%   -6.3%           -4.5%
WW                                                   386             522        -26.1%     -24.7%          -1.4%          1,221            1,682         -27.4%   -24.9%          -2.5%
TOTAL PHARMACEUTICAL
US                                                   5,042           4,509      11.8%      11.8%           -              15,123           13,423        12.7%    12.7%           -
Intl                                                 3,358           3,185      5.4%       5.0%            0.4%           10,109           9,943         1.7%     4.2%            -2.5%
WW                                                   $      8,400    7,694      9.2%       9.0%            0.2%           $      25,232    23,366        8.0%     9.1%            -1.1%
See footnotes at end of schedule
                                          REPORTED SALES vs. PRIOR PERIOD ($MM)
                                          THIRD QUARTER                                                                NINE MONTHS
                                                                                % Change                                                                 % Change
                                                     2016            2015       Reported   Operational (1) Currency       2016             2015          Reported Operational (1) Currency
MEDICAL DEVICES SEGMENT (2) (4)
CARDIOVASCULAR
US                                                   $         235   239        -1.7%      -1.7%           -              $           701  702           -0.1%    -0.1%           -
Intl                                                 216             285        -24.2%     -26.8%          2.6%           663              895           -25.9%   -25.6%          -0.3%
WW                                                   451             524        -13.9%     -15.3%          1.4%           1,364            1,597         -14.6%   -14.4%          -0.2%
DIABETES CARE
US                                                   191             205        -6.8%      -6.8%           -              548              631           -13.2%   -13.2%          -
Intl                                                 236             265        -10.9%     -11.2%          0.3%           779              817           -4.7%    -2.2%           -2.5%
WW                                                   427             470        -9.1%      -9.2%           0.1%           1,327            1,448         -8.4%    -7.0%           -1.4%
DIAGNOSTICS
US                                                   -               -          -          -               -              -                -             -        -               -
Intl                                                 7               16         -56.3%     -55.8%          -0.5%          66               62            6.5%     21.1%           -14.6%
WW                                                   7               16         -56.3%     -55.8%          -0.5%          66               62            6.5%     21.1%           -14.6%
ORTHOPAEDICS
US                                                   1,343           1,312      2.4%       2.4%            -              4,099            3,942         4.0%     4.0%            -
Intl                                                 908             869        4.5%       4.5%            0.0%           2,848            2,897         -1.7%    0.9%            -2.6%
WW                                                   2,251           2,181      3.2%       3.2%            0.0%           6,947            6,839         1.6%     2.7%            -1.1%
HIPS
US                                                   190             185        2.7%       2.7%            -              590              568           3.9%     3.9%            -
Intl                                                 130             124        4.8%       6.4%            -1.6%          421              410           2.7%     6.5%            -3.8%
WW                                                   320             309        3.6%       4.2%            -0.6%          1,011            978           3.4%     5.0%            -1.6%
KNEES
US                                                   223             214        4.2%       4.2%            -              696              662           5.1%     5.1%            -
Intl                                                 132             129        2.3%       4.0%            -1.7%          433              429           0.9%     4.3%            -3.4%
WW                                                   355             343        3.5%       4.1%            -0.6%          1,129            1,091         3.5%     4.8%            -1.3%
TRAUMA
US                                                   389             368        5.7%       5.7%            -              1,151            1,083         6.3%     6.3%            -
Intl                                                 248             239        3.8%       3.1%            0.7%           764              801           -4.6%    -2.1%           -2.5%
WW                                                   637             607        4.9%       4.6%            0.3%           1,915            1,884         1.6%     2.7%            -1.1%
SPINE & OTHER
US                                                   541             545        -0.7%      -0.7%           -              1,662            1,629         2.0%     2.0%            -
Intl                                                 398             377        5.6%       5.0%            0.6%           1,230            1,257         -2.1%    0.0%            -2.1%
WW                                                   939             922        1.8%       1.6%            0.2%           2,892            2,886         0.2%     1.1%            -0.9%
SURGERY
US                                                   1,002           987        1.5%       1.5%            -              3,003            2,947         1.9%     1.9%            -
Intl                                                 1,282           1,233      4.0%       3.9%            0.1%           3,906            3,857         1.3%     4.3%            -3.0%
WW                                                   2,284           2,220      2.9%       2.9%            0.0%           6,909            6,804         1.5%     3.2%            -1.7%
ADVANCED
US                                                   390             357        9.2%       9.2%            -              1,131            1,046         8.1%     8.1%            -
Intl                                                 494             438        12.8%      13.0%           -0.2%          1,478            1,359         8.8%     11.9%           -3.1%
WW                                                   884             795        11.2%      11.3%           -0.1%          2,609            2,405         8.5%     10.3%           -1.8%
GENERAL
US                                                   414             427        -3.0%      -3.0%           -              1,254            1,272         -1.4%    -1.4%           -
Intl                                                 649             656        -1.1%      -1.1%           0.0%           2,006            2,063         -2.8%    0.0%            -2.8%
WW                                                   1,063           1,083      -1.8%      -1.8%           0.0%           3,260            3,335         -2.2%    -0.5%           -1.7%
SPECIALTY
US                                                   198             203        -2.5%      -2.5%           -              618              629           -1.7%    -1.7%           -
Intl                                                 139             139        0.0%       -1.2%           1.2%           422              435           -3.0%    0.3%            -3.3%
WW                                                   337             342        -1.5%      -2.0%           0.5%           1,040            1,064         -2.3%    -1.0%           -1.3%
VISION CARE
US                                                   277             262        5.7%       5.7%            -              767              758           1.2%     1.2%            -
Intl                                                 462             421        9.7%       5.3%            4.4%           1,297            1,202         7.9%     7.7%            0.2%
WW                                                   739             683        8.2%       5.5%            2.7%           2,064            1,960         5.3%     5.2%            0.1%
TOTAL MEDICAL DEVICES
US                                                   3,048           3,005      1.4%       1.4%            -              9,118            8,980         1.5%     1.5%            -
Intl                                                 3,111           3,089      0.7%       -0.2%           0.9%           9,559            9,730         -1.8%    0.5%            -2.3%
WW                                                   $      6,159    6,094      1.1%       0.7%            0.4%           $      18,677    18,710        -0.2%    1.0%            -1.2%
* Percentage greater than 100%
** Not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Reported as U.S. sales
(4) Prior year amounts have been reclassified to conform to current year product disclosure

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/johnson--johnson-reports-2016-third-quarter-results-300346521.html

SOURCE Johnson & Johnson

http://rt.prnewswire.com/rt.gif?NewsItemId=NY19407&Transmission_Id=201610180640PR_NEWS_USPR_____NY19407&DateId=20161018



Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2017 StockSelector.com. All rights reserved.